Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) gapped down before the market opened on Thursday. The stock had previously closed at $17.95, but opened at $15.38. SELLAS Life Sciences Group shares last traded at $15.7370, with a volume of 15,143,438 shares changing hands.
Recent SELLAS Life Sciences Group Headlines
These are some of the SLS headlines that stood out recently:
- Positive Sentiment: SELLAS reported positive Phase 3 REGAL trial data for galinpepimut-S in acute myeloid leukemia, a potential clinical catalyst for its cancer-treatment pipeline. Article: Positive Phase 3 REGAL trial data
- Positive Sentiment: The $150 million offering will provide capital to support development of the company’s oncology candidates, including GPS and SLS009. Article: SELLAS prices $150 million offering
- Negative Sentiment: SELLAS priced 11.54 million new shares at $13 each, with an underwriter option for up to 1.73 million additional shares. The added supply and discounted price raise dilution concerns and are the immediate reported catalyst for the stock’s decline; the offering is expected to close November 20. Article: Shares sink after offering pricing
Analysts Set New Price Targets
A number of equities analysts have recently commented on SLS shares. Alliance Global Partners restated a "buy" rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $10.00.
View Our Latest Research Report on SELLAS Life Sciences Group
SELLAS Life Sciences Group Trading Down 18.3%
The stock has a market cap of $2.99 billion, a PE ratio of -72.52 and a beta of 2.73. The company's 50 day moving average is $11.09 and its 200-day moving average is $8.94.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05).
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its position in shares of SELLAS Life Sciences Group by 293.2% during the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company's stock worth $27,000 after buying an additional 1,630 shares in the last quarter. California State Teachers Retirement System raised its holdings in SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after acquiring an additional 1,709 shares in the last quarter. Nykredit A S acquired a new stake in SELLAS Life Sciences Group in the second quarter valued at $27,000. Robinhood Markets Inc. acquired a new stake in SELLAS Life Sciences Group in the third quarter valued at $33,000. Finally, Pictet Asset Management Holding SA raised its holdings in SELLAS Life Sciences Group by 15.4% in the third quarter. Pictet Asset Management Holding SA now owns 27,688 shares of the company's stock valued at $341,000 after acquiring an additional 3,704 shares in the last quarter. Hedge funds and other institutional investors own 17.38% of the company's stock.
SELLAS Life Sciences Group Company Profile
(
Get Free Report)
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms' tumor 1 (WT1) protein, which is found in several types of cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.